Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants With Anemia Due to Low-risk Myelodysplastic Syndrome

NCT06847867 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06847867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06847867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants With Anemia Due to Low-risk Myelodysplastic Syndrome
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Recruiting
Start date
June 5, 2025
Completion date
December 29, 2027
Enrollment
80 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes